Attenuated measles virus used as an oncolytic virus activates myeloid and plasmacytoid dendritic cells

Attenuated measles viruses (MV) are assessed in clinical trials for their capacity to preferentially infect and kill tumor cells. we recently showed that MV-infected tumor cells are able to activate tumor antigen cross-presentation by myeloid and plasmacytoid dendritic cells. thus, MV-based antitumor virotherapy may stimulate antitumor immune response.